Innoviva, Inc.
About Innoviva, Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $411.3M
- Net income
- $4.4M
- Total assets
- $1.6B
- Market cap
- $1.7B
- Gross margin
- 74.8%
- Operating margin
- 39.8%
- Net margin
- 65.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $411.3M
- Cost of revenue
- $103.7M
- Gross profit
- $307.7M
- Operating expenses
- $143.9M
- Operating income
- $163.7M
- Income tax
- $55.7M
- Net income
- $271.2M
- EPS (basic)
- $4.02
- EPS (diluted)
- $3.30
Balance sheet
- Total assets
- $1.6B
- Current assets
- $727.5M
- Total liabilities
- $462.3M
- Current liabilities
- $49.7M
- Shareholders’ equity
- $1.2B
Cash flow
- Operating cash flow
- $196.9M
- Investing cash flow
- $40.5M
- Financing cash flow
- $8.6M
- Net cash flow
- $246.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.7B
- P/E ratio
- 6.8
- EPS (diluted)
- $3.3
- Dividend yield
- 4.48%
- Shares outstanding
- 74.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 5, 2004
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $4.4M in FY2025.
- Revenue grew 5% from FY2021 to FY2025.
- Gross margin of 74.8%, net margin 65.9%.
- Trading 8% below its 52-week high.
- Pays a dividend yielding about 4.48% annually.
- Valued at a price-to-earnings (P/E) ratio of 6.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Innoviva, Inc..
Write a review
News about Innoviva, Inc.
News & sentiment via Polygon.io
